Retatrutide
Retatrutide (GLP-1/GIP/GCGR Triple Receptor Agonist)
Evidence & Status
- Strong Human Evidence
- Strong
At a Glance
An investigational once-weekly triple agonist targeting GIP, GLP-1, and glucagon receptors. Lilly reported Phase 3 topline average weight-loss results of up to 20.8% at 80 weeks in TRIUMPH-2 and up to 22.6% at 80 weeks in TRIUMPH-3. The complete trial reports have not yet been peer reviewed, and retatrutide is not FDA approved.
Plain English
Researchers study Retatrutide because one molecule activates three hormone pathways involved in metabolic regulation: GIP, GLP-1, and glucagon receptors. Lilly has reported topline results from multiple Phase 3 TRIUMPH trials, including average weight loss of up to 20.8% at 80 weeks in TRIUMPH-2 and up to 22.6% at 80 weeks in TRIUMPH-3. These company-reported results have not yet been published as complete peer-reviewed trial reports. Lilly plans a U.S. filing in Q1 2027, but retatrutide remains investigational and is not FDA approved.
Overview
Retatrutide (LY3437943) is an investigational once-weekly single-molecule agonist of the GIP, GLP-1, and glucagon receptors. Published Phase II trials and sponsor-reported Phase 3 topline results have examined obesity and type 2 diabetes populations. The TRIUMPH-2 and TRIUMPH-3 topline results have not yet been published as complete peer-reviewed trial reports. Retatrutide remains investigational and is not FDA approved.
Research Summary
Retatrutide has published controlled Phase II evidence and sponsor-reported Phase 3 topline results while it remains investigational. In TRIUMPH-2 (NCT05929079), 1,152 adults with type 2 diabetes and obesity or overweight were randomized; Lilly reported average body-weight changes at 80 weeks of -12.7% with 4 mg, -19.1% with 9 mg, and -20.8% with 12 mg, compared with -4.0% with placebo. In TRIUMPH-3 (NCT05882045), 1,949 adults with severe obesity and established cardiovascular disease, with or without type 2 diabetes, were randomized; Lilly reported average body-weight changes at 80 weeks of -21.6% with 9 mg and -22.6% with 12 mg, compared with -3.2% with placebo. These are company-reported topline results and have not yet been published as complete peer-reviewed trial reports; the registry records confirm trial identity and design but do not currently provide posted results. TRIUMPH-3 included exploratory/event analyses of major cardiovascular events, but the reported estimates were imprecise and do not establish cardiovascular-event reduction. Lilly announced plans to submit a U.S. Biologics License Application (BLA) for retatrutide in Q1 2027. A planned filing is not a submitted application or approval. Retatrutide is not FDA approved, and no approved dosing exists. Emerging preclinical research has also examined retatrutide in obesity-associated cancer models. In mouse models of pancreatic cancer, retatrutide delayed tumor onset and progression and produced a 14-fold reduction in tumor volume compared with controls. In a lung cancer model, tumor engraftment was reduced by 50%, tumor onset was delayed, and tumor volume was reduced 17-fold compared with controls. These findings are preclinical; anticancer effectiveness has not been established in humans. In an October 28, 2026 sponsor announcement, Lilly reported TRANSCEND-T2D-2 (NCT06260722), a Phase 3 randomized, open-label comparison in adults with type 2 diabetes inadequately controlled on metformin, with or without an SGLT2 inhibitor. Lilly reported 1,298 participants; the registry's estimated enrollment is not a verified final participant count. At 80 weeks, efficacy-estimand A1C changes were -2.2 percentage points with retatrutide 9 mg and -2.2 with 12 mg versus -1.8 with semaglutide (Ozempic) 2 mg. Weight changes were -19.5% (-20.1 kg), -20.9% (-21.5 kg) and -9.4% (-9.5 kg), respectively. The primary objective was A1C noninferiority of 12 mg versus semaglutide 2 mg. A1C superiority for 12 mg and weight superiority for both doses were reported at p<0.001 with family-wise type 1 error control; A1C superiority for 9 mg was nominal p<0.001, while 9 mg A1C noninferiority was a multiplicity-controlled key secondary endpoint. In the same arm order (9 mg, 12 mg, semaglutide 2 mg), reported adverse events included diarrhea (28.3%, 32.7%, 26.4%), nausea (21.2%, 23.8%, 21.3%), constipation (14.2%, 13.1%, 19.8%), vomiting (10.2%, 15.0%, 13.2%) and dyspepsia (10.4%, 8.5%, 11.6%). Dysesthesia occurred in 4.8%, 6.5% and 2.7%; adverse-event discontinuation in 4.8%, 7.9% and 2.7%. Lilly described most of these events as mild-to-moderate and typically resolving during treatment. The efficacy estimand assumes randomized participants remained on intervention for 80 weeks, allowing interruptions/modifications, without additional antihyperglycemic medication for more than 14 days; these figures are not an all-participant treatment-policy estimate. These are sponsor-reported topline results, not an independently published full trial report; detailed peer-reviewed publication is pending. Open-label design, incomplete published detail and unresolved long-term safety limit interpretation. These results do not establish cardiovascular-outcome benefit, safety or effectiveness for an approved use, or regulatory approval.
Research Areas
- Investigational obesity research
- Investigational type 2 diabetes research
- Cancer research (animal models)
Safety & Risks
Serious Risks
- Long-term human safety and clinical outcomes remain incompletely characterized; not approved for use outside clinical trials
Reported Side Effects
- Nausea
- Vomiting
- Diarrhea
- Decreased appetite
- Constipation
- Dysesthesia
- Injection site reactions
- Elevated heart rate (dose-dependent)
- Decreased lean mass at highest doses
Legal Status by Region
- United States
- Investigational; not FDA approved. Lilly announced plans to submit a U.S. Biologics License Application (BLA) for retatrutide in Q1 2027; a planned filing is not a submitted application or approval
- United Kingdom
- Current authorization status not established in this record
- Australia
- Current authorization status not established in this record
- Canada
- Current authorization status not established in this record
Citations & Sources
- Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial
The New England Journal of Medicine · 2023
PMID 37366315 · DOI 10.1056/NEJMoa2301972
- Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA
Lancet · 2023
PMID 37385280 · DOI 10.1016/S0140-6736(23)01053-X
- TRIUMPH-1: Retatrutide in adults with obesity or overweight (NCT05929066).
Registry NCT05929066
- The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes).
Registry NCT06383390
- Incretin triple agonist retatrutide (LY3437943) alleviates obesity-associated cancer progression
npj Metabolic Health and Disease · 2025
PMID 40094000 · DOI 10.1038/s44324-025-00054-5
- Lilly's triple agonist, retatrutide, successful in two additional Phase 3 obesity trials, delivering significant improvements in weight and A1C
Eli Lilly and Company · Eli Lilly and Company · 2026
- TRIUMPH-2 Phase 3 trial of retatrutide (NCT05929079)
Registry NCT05929079
- TRIUMPH-3 Phase 3 trial of retatrutide (NCT05882045)
Registry NCT05882045
- Sponsor announcement (TRANSCEND-T2D-2; NCT06260722): Lilly's retatrutide delivered greater A1C reduction and more than double the weight loss of Ozempic's highest approved dose in head-to-head trial
Eli Lilly and Company · Lilly News Release — sponsor-reported topline results; full peer-reviewed report pending · 2026
- Effect of Retatrutide Compared With Semaglutide in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin With or Without SGLT2 Inhibitor (TRANSCEND-T2D-2)
Registry NCT06260722